Table 2 Percentage of aneuploid cells in... | American Society of Hematology

Table 2

Percentage of aneuploid cells in direct (uncultured) condition

Probe	Visit	Control		G-CSF		P
Probe	Visit	Mean	SD	Mean	SD	P
CEP7	Baseline	1.9	0.9	1.9	0.9	.74
Day 5	1.6	0.7	1.7	0.9	0.83
Month 2	2.2	0.8	2.5	1.1	0.51
Month 6	2.2	0.8	2.5	0.9	0.25
Month 12	1.9	0.8	2.1	1.0	0.41
ELN	Baseline	1.1	0.7	1.0	0.7	.60
Day 5	1.4	0.8	0.8	0.6	0.01*
Month 2	1.5	0.7	1.3	0.7	0.51
Month 6	1.4	0.7	1.3	0.8	0.53
Month 12	1.4	0.9	1.4	0.8	0.52
D7S486	Baseline	1.0	0.6	1.2	0.9	.77
Day 5	1.2	0.8	0.9	0.7	0.14
Month 2	1.5	0.8	1.5	0.8	0.84
Month 6	1.3	0.7	1.8	0.7	0.06
Month 12	1.0	0.7	1.4	0.8	0.06
RUNX1T1	Baseline	0.9	0.9	1.0	1.0	.72
Day 5	0.8	0.6	0.5	0.5	0.15
Month 2	1.0	0.8	1.0	0.7	0.95
Month 6	1.2	0.6	1.2	0.7	0.99
Month 12	1.2	0.6	1.3	0.7	0.67
ABL1	Baseline	2.0	0.8	2.0	0.8	.98
Day 5	2.3	0.9	1.8	1.0	0.14
Month 2	2.5	1.0	2.4	1.0	0.67
Month 6	2.3	0.7	2.5	0.9	0.58
Month 12	2.8	1.0	2.8	0.8	0.78
TP53	Baseline	2.6	1.0	2.9	1.2	.56
Day 5	2.7	0.8	2.4	1.1	0.41
Month 2	2.7	0.9	2.7	0.8	0.58
Month 6	3.0	1.0	2.8	1.2	0.53
Month 12	2.9	0.9	2.9	1.0	0.80
CEP17	Baseline	3.6	1.2	3.3	1.2	.66
Day 5	3.7	1.3	2.9	1.3	0.06
Month 2	4.2	1.3	4.0	1.0	0.93
Month 6	4.5	1.1	4.4	0.9	0.57
Month 12	4.9	1.1	4.4	1.2	0.19
RUNX1	Baseline	2.0	0.8	1.8	0.9	.42
Day 5	2.1	0.9	2.0	1.2	0.87
Month 2	2.3	0.8	2.5	1.1	0.65
Month 6	2.4	1.0	2.2	0.8	0.45
Month 12	2.3	0.9	2.3	0.8	0.93
BCR	Baseline	1.8	0.9	1.5	0.7	.35
Day 5	1.4	0.8	1.6	0.7	0.35
Month 2	2.0	1.3	2.0	0.9	0.86
Month 6	1.9	0.9	2.1	0.8	0.22
Month 12	2.3	1.1	2.2	0.9	0.75

Probe	Visit	Control		G-CSF		P
Probe	Visit	Mean	SD	Mean	SD	P
CEP7	Baseline	1.9	0.9	1.9	0.9	.74
Day 5	1.6	0.7	1.7	0.9	0.83
Month 2	2.2	0.8	2.5	1.1	0.51
Month 6	2.2	0.8	2.5	0.9	0.25
Month 12	1.9	0.8	2.1	1.0	0.41
ELN	Baseline	1.1	0.7	1.0	0.7	.60
Day 5	1.4	0.8	0.8	0.6	0.01*
Month 2	1.5	0.7	1.3	0.7	0.51
Month 6	1.4	0.7	1.3	0.8	0.53
Month 12	1.4	0.9	1.4	0.8	0.52
D7S486	Baseline	1.0	0.6	1.2	0.9	.77
Day 5	1.2	0.8	0.9	0.7	0.14
Month 2	1.5	0.8	1.5	0.8	0.84
Month 6	1.3	0.7	1.8	0.7	0.06
Month 12	1.0	0.7	1.4	0.8	0.06
RUNX1T1	Baseline	0.9	0.9	1.0	1.0	.72
Day 5	0.8	0.6	0.5	0.5	0.15
Month 2	1.0	0.8	1.0	0.7	0.95
Month 6	1.2	0.6	1.2	0.7	0.99
Month 12	1.2	0.6	1.3	0.7	0.67
ABL1	Baseline	2.0	0.8	2.0	0.8	.98
Day 5	2.3	0.9	1.8	1.0	0.14
Month 2	2.5	1.0	2.4	1.0	0.67
Month 6	2.3	0.7	2.5	0.9	0.58
Month 12	2.8	1.0	2.8	0.8	0.78
TP53	Baseline	2.6	1.0	2.9	1.2	.56
Day 5	2.7	0.8	2.4	1.1	0.41
Month 2	2.7	0.9	2.7	0.8	0.58
Month 6	3.0	1.0	2.8	1.2	0.53
Month 12	2.9	0.9	2.9	1.0	0.80
CEP17	Baseline	3.6	1.2	3.3	1.2	.66
Day 5	3.7	1.3	2.9	1.3	0.06
Month 2	4.2	1.3	4.0	1.0	0.93
Month 6	4.5	1.1	4.4	0.9	0.57
Month 12	4.9	1.1	4.4	1.2	0.19
RUNX1	Baseline	2.0	0.8	1.8	0.9	.42
Day 5	2.1	0.9	2.0	1.2	0.87
Month 2	2.3	0.8	2.5	1.1	0.65
Month 6	2.4	1.0	2.2	0.8	0.45
Month 12	2.3	0.9	2.3	0.8	0.93
BCR	Baseline	1.8	0.9	1.5	0.7	.35
Day 5	1.4	0.8	1.6	0.7	0.35
Month 2	2.0	1.3	2.0	0.9	0.86
Month 6	1.9	0.9	2.1	0.8	0.22
Month 12	2.3	1.1	2.2	0.9	0.75

P < .05 (Wilcoxon rank-sum test).